Peculiarities of blood coagulation disorders in patients with COVID-19

Peculiarities of blood coagulation disorders in patients with COVID-19

Blog Article

Aim.To study the relationship of hemostatic Science Projects disorders with inflammation and estimate their role in the course and outcomes of COVID-19.Materials and methods.We examined 215 consecutive patients with moderate and severe forms of acute COVID-19.

The patients were on anticoagulants and immunosuppressive drugs.Hemostasis was assessed using the thrombodynamics assay, thromboelastography, fibrinogen and D-dimer levels, prothrombin time, and soluble fibrin-monomer complexes (ethanol gelation test).The hemostatic parameters were correlated with hematological and biochemical tests, including markers of inflammation (C-reactive protein, interleukins 6 and 8), as well as with the disease severity and outcomes.Results.

Laboratory signs of coagulopathy were revealed in the vast majority of the cases.Despite the use of low-molecular-weight heparins in the prophylactic and therapeutic doses, coagulopathy in COVID-19 manifested predominantly as hypercoagulability that correlated directly with the systemic inflammation and metabolic changes due to liver and kidney dysfunction.A direct relationship was found between the grade of coagulopathy and the severity of COVID-19, including comorbidities and the mortality.The chronometric hypocoagulability observed in about 1/4 cases was associated with a high level of C-reactive protein, which may decelerate coagulation in vitro and thereby mask the true inflammatory thrombophilia.

Persistent hyperfibrinogenemia and high D-dimer in the absence of consumption coagulopathy suggest the predominance of local and/or regional microthrombosis over disseminated intravascular coagulation.Conclusion.The results obtained substantiate the need for laboratory monitoring of hemostasis and Body active prophylaxis and treatment of thrombotic complications in COVID-19.